US009511043B2

(12) **United States Patent**
Dyakonov et al.

(10) **Patent No.: US 9,511,043 B2**
(45) **Date of Patent: *Dec. 6, 2016**

(54) **FUMARATE ESTER PHARMACEUTICAL COMPOSITIONS**

(71) Applicant: **BANNER LIFE SCIENCES LLC**, High Point, NC (US)

(72) Inventors: **Tatyana Dyakonov**, Greensboro, NC (US); **Sunil Agnihotri**, Falmouth, ME (US); **Aqeel A. Fatmi**, High Point, NC (US)

(73) Assignee: **Banner Life Sciences LLC**, High Point, NC (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **15/073,714**

(22) Filed: **Mar. 18, 2016**

(65) **Prior Publication Data**

US 2016/0199335 A1 Jul. 14, 2016

Related U.S. Application Data

(62) Division of application No. 14/633,164, filed on Feb. 27, 2015, now Pat. No. 9,326,965.

(60) Provisional application No. 61/946,233, filed on Feb. 28, 2014, provisional application No. 61/950,648, filed on Mar. 10, 2014, provisional application No. 62/011,604, filed on Jun. 13, 2014, provisional application No. 62/061,185, filed on Oct. 8, 2014.

(51) **Int. Cl.**

A61K 8/04	(2006.01)
A61K 9/48	(2006.01)
A61K 47/44	(2006.01)
A61K 8/37	(2006.01)
A61K 31/225	(2006.01)
A61K 45/06	(2006.01)
A61K 47/32	(2006.01)
A61K 47/14	(2006.01)
A61K 9/00	(2006.01)
A61K 47/12	(2006.01)
A61K 47/46	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/225*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 9/48*** (2013.01); ***A61K 9/4858*** (2013.01); ***A61K 9/4875*** (2013.01); ***A61K 9/4891*** (2013.01); ***A61K 45/06*** (2013.01); ***A61K 47/12*** (2013.01); ***A61K 47/14*** (2013.01); ***A61K 47/32*** (2013.01); ***A61K 47/44*** (2013.01); ***A61K 47/46*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,146,730	A	9/1992	Dietel	
5,424,332	A	6/1995	Speiser	
5,459,983	A	10/1995	Dietel	
6,355,676	B1	3/2002	Joshi	
6,436,992	B1	8/2002	Joshi	
6,482,516	B1	11/2002	Dietel	
6,509,376	B1	1/2003	Joshi	
7,157,423	B2	1/2007	Joshi	
7,320,999	B2	1/2008	Joshi	
7,432,240	B2	10/2008	Joshi	
7,612,110	B2	11/2009	Joshi	
7,619,001	B2	11/2009	Joshi	
7,803,840	B2	9/2010	Joshi	
7,915,310	B2	3/2011	Joshi	
8,293,270	B2	10/2012	Sukuru	
8,333,989	B2	12/2012	Sukuru	
8,399,514	B2	3/2013	Gilmore	
8,524,773	B2	9/2013	Joshi	
8,669,281	B1	3/2014	Sanrame	
8,669,282	B2	3/2014	Zicker	
8,685,445	B2	4/2014	Hassan	
8,759,393	B2	6/2014	Joshi	
9,090,558	B2	7/2015	Zeidan	
9,326,947	B1 *	5/2016	Dyakonov	A61K 9/4875
9,326,965	B2 *	5/2016	Dyakonov	A61K 31/225
2003/0018072	A1	1/2003	Joshi	
2004/0054001	A1	3/2004	Joshi	
2006/0051345	A1	3/2006	Frohna	
2006/0115527	A1	6/2006	Chidambaram	
2006/0165778	A1	7/2006	Hassan	
2007/0104778	A1 *	5/2007	Zeng	A61K 9/1075 424/451
2008/0004344	A1	1/2008	Nilsson	
2008/0233185	A1	9/2008	Joshi	
2008/0299196	A1	12/2008	Nilsson	

(Continued)

FOREIGN PATENT DOCUMENTS

EP	0312697 A2	4/1989
WO	0030622	6/2000

(Continued)

OTHER PUBLICATIONS

TECFIDERA® Prescribing Information Mar. 2013 (Biogen Idec).

Sheikh et al., "Tolerability and pharmacokinetics of delayed-release dimethyl fumarate administered with and without aspirin in healthy volunteers," Clinical Therapeutics 35(10): 1582-1594 (2013).

Schimrigk et al., "Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study," European J. Neurology 13(6): 604-610 (2006).

(Continued)

Primary Examiner — Abigail Fisher

(74) *Attorney, Agent, or Firm* — Brinks Gilson & Lione

(57) **ABSTRACT**

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.

29 Claims, 13 Drawing Sheets